Cosmos Health to Launch Liv18 Supplement in Q2 Targeting $7B MASLD Market
Cosmos Health plans Q2 2026 U.S. rollout of Liv18, a liver health supplement powered by patented BergacynFF®, clinically shown to reduce liver fat by up to 15% and support 9.6 lb weight loss in trials. The launch targets a $7B+ MASLD market projected to grow at 4.9% CAGR through 2035.
1. Q2 U.S. Launch of Liv18
Cosmos Health plans to introduce Liv18™ in the United States during Q2 2026, offering a 600 mg per serving supplement powered by patented BergacynFF®, a blend of bergamot polyphenols and artichoke sesquiterpenes. All products will be manufactured in GMP-certified, FDA-registered U.S. facilities.
2. Clinical Trial Results
Liv18™’s core ingredient, BergacynFF®, has demonstrated a 15% reduction in liver fat and 9.6 lb average weight loss versus placebo in two independent randomized, double-blind, placebo-controlled trials over 12 to 16 weeks. Trial data also showed significant improvements in ALT and AST levels, along with antioxidant and cardioprotective benefits.
3. Market Opportunity and Distribution
The launch addresses a U.S. metabolic dysfunction-associated steatotic liver disease market exceeding $7 billion with projected 4.9% CAGR through 2035, where over 30% of adults are affected. Distribution will span e-commerce, health and specialty retail, and healthcare practitioner channels, supported by targeted consumer outreach.